Welcome to our dedicated page for Simulations Plus news (Ticker: SLP), a resource for investors and traders seeking the latest updates and insights on Simulations Plus stock.
Simulations Plus, Inc. (Nasdaq: SLP) is frequently in the news for developments at the intersection of biosimulation software, cheminformatics, and AI‑enabled drug development. Company press releases cover its role as a global leader in model‑informed and AI‑accelerated drug development, highlighting how its software and services support pharmaceutical and biotechnology organizations throughout the drug lifecycle.
News items commonly include quarterly and annual financial results, where Simulations Plus reports revenue contributions from its software and services segments, discusses demand trends, and provides guidance ranges for future periods. Management commentary often addresses bookings in software and services, adoption of cloud deployment and AI‑driven workflows, and the impact of market conditions on client spending.
Investors following SLP news will also see announcements about product strategy and AI initiatives, such as the company’s integrated, AI‑enabled modeling ecosystem connecting platforms like GastroPlus®, MonolixSuite®, ADMET Predictor®, and QSP/QST tools. Releases describe cloud‑scale compute, AI copilots that guide complex modeling workflows, and an AI‑orchestrated framework designed to support multi‑engine simulations and decision support.
The company’s news flow includes scientific and collaboration updates, for example validation of AI‑driven drug design in ADMET Predictor® through collaborations and published case studies, and commentary on alignment with regulatory guidance for model‑informed nonclinical safety assessments. Additional items cover investor events such as conference presentations and virtual Investor Day sessions that provide detail on long‑term strategy, product roadmaps, and financial outlook.
By monitoring the SLP news page, readers can track how Simulations Plus communicates its financial performance, advances in biosimulation and AI, regulatory‑aligned modeling capabilities, and strategic initiatives within the biopharma technology landscape.
Simulations Plus has announced a new funded collaboration with a major animal health company to enhance its GastroPlus platform. This partnership aims to validate existing animal physiologically based pharmacokinetic (PBPK) models and introduce new species to the platform. The collaboration will bolster veterinary medicine and food production research, promoting animal welfare and public health. Leaders from Simulations Plus emphasized the significance of this expansion into animal health markets, aiming to develop innovative modeling tools.
Simulations Plus, Inc. (NASDAQ: SLP) announced that CEO Shawn O’Connor will present at the Sidoti Winter Small Cap Investor Conference on January 19–20, 2022. O’Connor's presentation is scheduled for January 19, 2022, at 4:00 p.m. ET. Investors can access a live webcast through the Sidoti website. Simulations Plus, a leader in biosimulation, supports drug discovery and development across the globe.
Simulations Plus, a leading modeling and simulation software provider, reported a 16% increase in total revenue for Q1 FY2022, reaching $12.4 million. Software revenue grew 19% to $7.4 million, constituting 59% of total revenue. Net income rose 22% to $3.0 million, with diluted EPS increasing to $0.15. The company announced a quarterly dividend of $0.06 per share, payable on February 7, 2022. CEO Shawn O’Connor expressed confidence in achieving 10-15% revenue growth guidance for the fiscal year, driven by an organic growth strategy and enhancements in software offerings.
Simulations Plus, Inc. (NASDAQ: SLP) announced an update to its MonolixSuite platform, enhancing PKanalix, Monolix, and Simulx modules. The update includes a new bioequivalence module with a user-friendly graphical interface for managing various study designs. New features such as R functions for reporting, a parent-metabolite library, and faster calculations for complex models have been introduced. These advancements aim to streamline the workflow for pharmacometricians, helping users conduct more efficient data analyses and simulations.
Simulations Plus, Inc. (NASDAQ: SLP) will report its financial results for Q1 FY 2022, ending November 30, 2021, on January 6, 2022, after market close. A conference call is scheduled for the same day at 5:00 PM ET, where all interested individuals can join by registering online or via phone. The company, a leader in simulation software for drug discovery and development, has been serving clients for 25 years, providing solutions to major pharmaceutical and regulatory firms globally. More information will be available on their website.
Simulations Plus has announced an extension of its distributor agreement in Japan with Northern Science Consulting for its Monolix software. This partnership builds on existing agreements for GastroPlus and ADMET Predictor, enhancing the company's presence in the Japanese pharmaceutical market. The collaboration aims to boost awareness of Monolix and strengthen relationships with local businesses and universities, reflecting a growing user community in the region.
Summary not available.
Summary not available.
Simulations Plus, Inc. (Nasdaq: SLP) has appointed Sharlene Evans to its Board of Directors, replacing retiring board member David L. Ralph. Evans brings over 25 years of experience in operations and human resources, previously serving as Chief People Officer at Myrtle Consulting Group. She will participate in the Audit and Compensation committees and stand for election at the company’s Annual General Meeting in February 2022. This leadership change aims to strengthen talent management as the company seeks continued growth in the modeling and simulation software sector.
Simulations Plus (Nasdaq: SLP) presented findings at The Liver Meeting that connect yo-yo dieting to increased placebo response rates in clinical trials for non-alcoholic steatohepatitis (NASH). The research suggests that minor dietary changes can significantly reduce fibrosis scores, a critical measure for treatment efficacy. This insight could aid in addressing the perplexing high placebo response rates observed in numerous clinical trials, potentially improving the viability of various treatment candidates for NASH.